.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,061,492

« Back to Dashboard

Details for Patent: 5,061,492

Title: Prolonged release microcapsule of a water-soluble drug
Abstract:A microcapsule produced by preparing a water-in-oil emulsion comprising an inner aqueous layer containing said water-soluble drug and a drug retaining substance therefor and an oil layer containing a polymer substance, then thickening or solidifying said inner aqueous layer to a viscosity of not lower than about 5000 centiposes and finally subjecting the resulting emulsion to in water drying gives prolonged release of water-soluble drug.
Inventor(s): Okada; Hiroaki (Osaka, JP), Ogawa; Yasuaki (Osaka, JP), Yashiki; Takatsuka (Hyogo, JP)
Assignee: Takeda Chemical Industries, Ltd. (Osaka, JP)
Filing Date:Jan 24, 1990
Application Number:07/469,784
Claims:1. An injectable preparation comprising a therapeutically effective amount of spherical microcapsules and a pharmaceutically acceptable vehicle, wherein said spherical microcapsules have an average diameter of 2-200 .mu.m, and comprise particles of a mixture of a water-soluble non-polypeptidic drug and a drug-retaining substance therefor selected from the group consisting of gelatin, albumin, pectin and agar, the weight ratio of the drug-retaining substance to the water-soluble non-polypeptidic drug being in the range of about 9/1 to about 0.3/1, the particles being dispersed in a spherical microcapsule matrix composed of a biodegradable polymer, said biodegradable polymer being a copolymer of lactic acid and glycolic acid having a comonomer ratio within the range of about 100/0 to 50/50 and an average molecular weight within the range of about 5,000 to 200,000.

2. An injectable preparation as recited in claim 1, wherein the water-soluble non-polypeptidic drug is a member selected from the group consisting of an antibiotic, an antitumor agent, an antipyretic, an analgesic, an anti-inflammatory agent, an antitussive, an expectorant, a sedative, a muscle relaxant, an antiepileptic, an antiulcer agent, an antidepressant, an antiallergic drug, a cardiotonic, an antiarrhythmic agent, a vasodilator, an antihypertensive diuretic, an antidiabetic, an anticoagulant, a hemostatic, an antituberculotic, a hormone drug and an antinarcotic.

3. An injectable preparation as recited in claim 2, wherein the antitumor agent is selected from the group consisting of bleomycin hydrochloride, methotrexate, actinomycin D, mitomycin C, vinblastine sulfate, vincristine sulfate, daunorubicin hydrochloride, adriamycin, neocarcinostatin, cytosine arabinoside, fluorouracil, krestin, picibanil, lentinan, levamisole, bestatin, azimexon, glycyrrhizin, poly I:C, poly A:U and poly ICLC.

4. An injectable preparation as recited in claim 1, wherein the water-soluble non-polypeptidic drug is an antitumor agent selected from the group consisting of bleomycin hydrochloride, methotrexate, actinomycin D, mitomycin C, vinblastine sulfate, vincristine sulfate, daunorubicin hydrochloride, adriamycin, neocarcinostatin, cytosine arabinoside, fluorouracil, krestin, picibanil, lentinan, levamisole, bestatin, azimexon, glycyrrhizin, poly I:C, poly A:U and poly ICLC.

5. An injectable preparation as recited in claim 4, wherein the antitumor agent is mitomycin C.

6. An injectable preparation as recited in claim 1, wherein the water-soluble non-polypeptidic drug is a member selected from the group consisting of sodium salicylate, sulpyrine, sodium flufenamate, sodium diclofenac, sodium indomethacin, morphine hydrochloride, pethidine hydrochloride, levorphanol tartrate and oxymorphone.

7. An injectable preparation as recited in claim 1, wherein the water-soluble non-polypeptidic drug is a member selected from the group consisting of sulpyrine, morphine hydrochloride and sodium diclofenac.

8. An injectable preparation as recited in claim 1, wherein the comonomer ratio of the copolymer of lactic acid and glycolic acid is about 78/22.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc